The study was funded by Edwards LifeSciences.

This study was simultaneously published online in The New England Journal of Medicine at the time of presentation.


The SAPIEN XT device used in this trial is an older model transcatheter. The same research team will present findings comparing the SAPIEN 3, the newest generation of the device, to surgery.

Vinod Thourani, M.D., professor of surgery and medicine and chief of cardiothoracic surgery at Emory Hospital Midtown and co-director of the Structural Heart and Valve Center at Emory University School of Medicine, will present that study, “Sapien 3 Transcatheter Aortic Valve Replacement versus Surgery in Intermediate-Risk Patients with Severe Aortic Stenosis: A Propensity-Matched Comparison of One-Year Outcomes,” on Sunday, April 3, 2016, at 10:45 a.m. CT/11:45 a.m. ET/3:45 p.m. UTC in the Main Tent (North Hall B1).

The ACC’s Annual Scientific Session, which in 2016 will be April 2-4 in Chicago, brings together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC16 for the latest news from the meeting. The American College of Cardiology is a 52,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.

- See more at: http://www.acc.org/about-acc/press-releases/2016/04/02/10/12/rates-of-death-and-stroke-equivalent-for-surgery-and-tavr-at-two-years?w_nav=S#sthash.2yKBtgAz.dpuf

Back to HCB News

Medical Research Homepage